Insming

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
  • Presented results from the randomized withdrawal phase of Study C602 at the Foundation for Prader-Willi Research (FPWR) 2023 Research Symposium held on October 5-6, 2023 in Denver, Colorado.
  • “The recent announcement of positive results from the randomized withdrawal phase of Study C602 was a significant milestone for us,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics.
  • The following table summarizes the Soleno’s outstanding common stock and common stock warrants as of October 31, 2023:

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023

& ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • Commercial sales have increased in the United States and European countries, including France, Germany and Italy, during the third quarter.
  • Since the beginning of 2023, we have launched KIMMTRAK in Austria, Israel, Italy, Finland, Switzerland and Belgium, and have recently reached price agreements with Canada and Australia.
  • Cash and cash equivalents were £364.0 million ($444.5 million) as of September 30, 2023, compared to £332.5 million as of December 31, 2022.

Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe

Retrieved on: 
Thursday, November 2, 2023

BRIDGEWATER, N.J., Nov. 2, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today holds its second annual Global Day of Good, with hundreds of Insmed employees volunteering simultaneously in their respective communities.

Key Points: 
  • Today, Insmed will make an even greater impact, with more than 700 employees volunteering in 25 locations, benefitting over 20 organizations.
  • "I'm proud that Insmed's hometown of Bridgewater has been included as part of the Company's larger global effort to spur meaningful change for communities around the world."
  • "Today's hands-on activities exemplify our core values coming to life and reflect the purpose we live by every day.
  • The Company plans to hold its Global Day of Good annually to continue its impact on local communities.

Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List

Retrieved on: 
Thursday, October 26, 2023

BRIDGEWATER, N.J., Oct. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has earned the highest ranking in Science's 2023 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.

Key Points: 
  • The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.
  • "At Insmed, we know that our people are our most valuable asset, and it is because of them that we have received this honor once again.
  • The 2023 survey results were based on more than 6,800 responses from individuals across North America (59%), Europe (18%), Asia/Pacific Rim (16%), and other locations (7%).
  • Following Insmed, the top five companies in 2023 included Incyte, Alnylam, Regeneron, and Syngenta Group.

Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI

Retrieved on: 
Tuesday, October 24, 2023

Insmed has built a generative AI search capability using Vertex AI Search trained on its internal documentation, as well as separate functionality that enables indexed access to available, external medical publications.

Key Points: 
  • Insmed has built a generative AI search capability using Vertex AI Search trained on its internal documentation, as well as separate functionality that enables indexed access to available, external medical publications.
  • "This collaboration represents a multi-year commitment to bring about real change to the drug development process," said Will Lewis, chair and chief executive officer of Insmed.
  • "Insmed is using Google Cloud infrastructure and AI technology to power this transformation leveraging already available AI modules," said Mark Pellegrino, chief information officer of Insmed.
  • From the day we began to explore possibilities, Google Cloud has been in lockstep with Insmed's ambition to transform the life sciences ecosystem."

Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023

Retrieved on: 
Thursday, October 12, 2023

BRIDGEWATER, N.J., Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third-quarter 2023 financial results on Thursday, October 26, 2023.

Key Points: 
  • BRIDGEWATER, N.J., Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third-quarter 2023 financial results on Thursday, October 26, 2023.
  • Insmed management will host a conference call for investors beginning at 8:30 a.m.
  • ET on Thursday, October 26, 2023, to discuss the financial results and provide a business update.
  • Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S. and international) and referencing access code 7862189.

Chasing Breakthrough Innovation in a Time of Uncertainty With Insights from McKinsey & Company

Retrieved on: 
Tuesday, September 19, 2023

TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott. The C-Suite Summit brings together life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue to discuss the topics impacting C-Suite decision-making in bringing new innovative treatments to market.

Key Points: 
  • Friday, October 6, 2023 • 7:30 a.m.-4:00 p.m. Bridgewater Marriott, 700 Commons Way, Bridgewater
    TRENTON, N.J., Sept. 19, 2023 /PRNewswire/ -- BioNJ has released the agenda and speaker roster for its Eleventh Annual C-Suite Summit, taking place Friday, October 6, 2023, at the Bridgewater Marriott.
  • The C-Suite Summit brings together life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue to discuss the topics impacting C-Suite decision-making in bringing new innovative treatments to market.
  • "As the policy environment churns and investment in biopharma fluctuates, questions are being raised about the future of innovation for our industry," said BioNJ President and CEO, Debbie Hart.
  • "The C-Suite Summit allows stakeholders to come together for an open conversation on where the greatest opportunities lie and how to best prepare for and shape the next paradigm in life sciences and medical discovery."

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

Retrieved on: 
Wednesday, August 16, 2023

REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023.

Key Points: 
  • REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023.
  • Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience.
  • “Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board,” said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno.
  • In addition to his Board positions at Savara and Strongbridge, Mr. Pauls has also served as Chair of the Board of Directors of Mast Therapeutics and was a member of the Board of Directors of Zyla Life Sciences.

Inaugural World NTM Awareness Day Marks 20-Year Anniversary and Honors Founders' Mission on August 4, 2023

Retrieved on: 
Friday, August 4, 2023

MIAMI, Aug. 4, 2023 /PRNewswire/ -- NTM Info & Research ( www.ntminfo.org ), a pioneering global organization committed to addressing NonTuberculous Mycobacterial (NTM) and improving respiratory health, proudly announces the first-ever World NTM Awareness Day, to be held on August 4, 2023.

Key Points: 
  • MIAMI, Aug. 4, 2023 /PRNewswire/ -- NTM Info & Research ( www.ntminfo.org ), a pioneering global organization committed to addressing NonTuberculous Mycobacterial (NTM) and improving respiratory health, proudly announces the first-ever World NTM Awareness Day, to be held on August 4, 2023.
  • Nearly all NTM patients have bronchiectasis, either before or as a result of NTM.
  • "We are thrilled to announce the first World NTM Awareness Day as we commemorate our 20-year anniversary," said Leitman.
  • The inaugural World NTM Awareness Day will feature a virtual webinar and panel discussion featuring renowned experts, researchers, and advocates, providing valuable insights into the latest advancements in NTM diagnosis, treatment, and support.

Adrestia Acquired by Insmed Incorporated, Bringing its Novel Approach to Tackling Intractable Genetic Diseases to Insmed’s Early-Stage Research Portfolio

Retrieved on: 
Thursday, August 3, 2023

“Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.

Key Points: 
  • “Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.
  • With Insmed, we’re no longer dreaming big, we’re going big.”
    Adrestia’s synthetic rescue platform uses whole genome assays to identify drug targets for genetic diseases in a wide network of functionally connected genes.
  • Sir Steve is University of Cambridge Professor of Biology and Senior Group Leader at the Cancer Research UK Cambridge Institute.
  • J.P. Morgan Securities plc acted as exclusive financial adviser to Adrestia, and Goodwin Procter (UK) LLP acted as Adrestia’s legal counsel.